deltatrials
Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05098197

A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Hepatobiliary-Pancreatic Cancers

Sponsor: Shanghai 10th People's Hospital

Conditions Advanced Liver Cancers Advanced Pancreatic Cancers Effects of Immunotherapy Treatment Side Effects Tumor Infiltrating Lymphocyte
Interventions Tumor Infiltrating Lymphocyte
Updated 10 times since 2021 Last updated: Dec 4, 2025 Started: Sep 26, 2021 Primary completion: Sep 25, 2026 Completion: Sep 25, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Advanced Liver Cancers and Advanced Pancreatic Cancers and is currently actively recruiting participants. Shanghai 10th People's Hospital leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2021 – ~Jul 2022 · 8 months · monthly snapshotRecruiting~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshotRecruiting~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshotRecruiting~Jan 2023 – ~May 2024 · 16 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshotRecruiting~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshotRecruiting~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshotRecruiting~Jan 2026 – present · 7 months · monthly snapshotRecruiting

Change History

10 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting EARLY_PHASE1

  2. Sep 2025 — Jan 2026 [monthly]

    Recruiting EARLY_PHASE1

  3. Feb 2025 — Sep 2025 [monthly]

    Recruiting EARLY_PHASE1

  4. Sep 2024 — Feb 2025 [monthly]

    Recruiting EARLY_PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

▶ Show 5 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Recruiting EARLY_PHASE1

  2. Jan 2023 — May 2024 [monthly]

    Recruiting EARLY_PHASE1

  3. Sep 2022 — Jan 2023 [monthly]

    Recruiting EARLY_PHASE1

  4. Jul 2022 — Sep 2022 [monthly]

    Recruiting EARLY_PHASE1

  5. Nov 2021 — Jul 2022 [monthly]

    Recruiting EARLY_PHASE1

    First recorded

Sep 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai 10th People's Hospital
  • Shanghai Juncell Therapeutics
Data source: Shanghai Juncell Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations